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Objectives. Pregnant women, referred because of an increased risk of fetal Down syndrome, who underwent an invasive prenatal
procedure were offered a choice between karyotyping and rapid targeted testing. This study aims to assess women’s attitudes and
experiences towards what option to choose.Methods. A retrospective multicentre survey (2008–2010) was conducted among 1370
women. General questions were asked about decision making issues, followed by personal questions about their experiences in
choice making, test preference, influence of others, and possible regrets. Results. In total, 90.1% of the respondents (𝑁 = 825)
indicated that pregnant women are able to choose, although 33.1% stated that the choice can best be made by a professional. 18.4%
indicated that making a choice places a burden on women. In 96.4%, respondents preferred to have the option to choose again in
case of a next pregnancy, whereas 2.7% preferred the choice to be made by a professional. Regret was indicated by 1.2%. Decision
making was influenced by others in 64.9%. A slightly higher preference for karyotyping was indicated by 52.7% of the respondents.
Conclusions. Positive attitudes and experiences were expressed towards the option to choose. Respondents took decisions freely,
although sometimes influenced by a partner or a professional, to follow their individual perspectives.
1. Introduction
Currently, in many prenatal centres, rapid targeted tests (QF-
PCR: quantitative fluorescent polymerase chain reaction or
MLPA: multiplex ligation-dependent probe amplification)
are used for the prenatal detection of common chromosomal
aneuploidies.The need for rapid testing methods, not requir-
ing cell culture, has been recognized in order to improve
pregnancy management and to alleviate parental anxiety
[1, 2]. Analysis of large series of prenatal samples by QF-
PCR or MLPA has shown that both tests, deliberately
targeted to the analysis of selected chromosomes, that is,
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chromosomes 13, 18, and 21 with or without inclusion of the
sex chromosomes, allow the detection of the vast majority of
chromosome abnormalities in prenatal samples [3–9].
The application of such targeted tests as stand-alone tests
is still strongly debated in various countries, and therefore,
different approaches are presently applied. In some centers,
women with a risk of having a fetus with a chromosomal
abnormality (without fetal ultrasound anomalies) will only
be offered a rapid targeted test, whereas in other centres, they
can choose between a rapid targeted test and karyotyping or,
alternatively, are offered routine karyotyping only.
In the last decades, patient’s individual views, values,
and wishes have gradually become more important. Personal
autonomy and individualized choice have increasingly driven
patient’s autonomy to the forefront of health care [10],
particularly in prenatal testing [11]. In this regard freedom
of choice as to what test should be applied appears to be of
interest. So far, however, the question remains: what is the
patients’ experience?
During this study in our prenatal diagnostic centre, the
indications for prenatal testing were divided in seven main
indication groups (1)–(7) and examined with different types
of diagnostic tests (I)–(IV).
(I) A choice between karyotyping and rapid targeted
testing was offered to women with (1) advanced
maternal age (1) or to women with a risk > 1 : 250
following Down syndrome screening using the first
trimester combined test (2).
(II) Rapid targeted testing only (targets chromosomes 13,
18, 21, X, and Y) was offered when invasive testing was
performed for molecular or biochemical testing for a
genetic disorder (3).
(III) Karyotyping was performed when there are known
familial chromosome rearrangements, for example,
Robertsonian or reciprocal translocations (4) or a
known or suspected family history of chromosome
abnormality (5).
(IV) Genome-wide microarray analysis (after normal
rapid targeted test) was performed when there is
an ultrasound detection of any major structural
abnormality (including nuchal translucency> 3.5mm
before 14-week gestation) (6) or whether there is a
previous child with a submicroscopic aberration (7).
During the last four years, five hospitals within our
prenatal service program have offered pregnant women,
referred for an amniocentesis or chorionic villus sample
(CVS) because of advanced maternal age (maternal age ≥ 36
years) or a risk > 1 : 250 following Down syndrome screening
using the first trimester combined test, the option to choose
between a rapid targeted test and karyotyping as stand-alone
tests. The aim of the present study was to evaluate pregnant
women’s perspective and satisfaction towards the option to
choose between these tests.
Table 1: Personal characteristics of the 825 respondents.
Number %
Highest educational level (𝑁 = 824)
Lower vocational, lower secondary school 17 2.1
Intermediate and higher vocational,
higher secondary school 348 42.2
College/university 459 55.7
Respondents per hospital (𝑁 = 825)
A 292 35.4
B 187 22.7
C 94 11.4
D 96 11.6
E 156 18.9
Test of choice (𝑁 = 822) per hospital
Karyotyping (overall) 433 52.7
A 184 63.0
B 112 59.9
C 37 39.4
D 50 52.1
E 50 32.7
Rapid targeted test (overall) 333 40.5
A 91 31.2
B 60 32.1
C 50 53.2
D 40 41.7
E 92 60.1
Both (overall) 10 1.2
Unknown (overall) 46 5.6
2. Material and Methods
This retrospective survey involved the collection of infor-
mation from respondents by use of an anonymous ques-
tionnaire. After a pilot test with 50 questionnaires, the final
questionnaire was sent out in April 2011 to 1370 women who
underwent an invasive procedure in the period from March
2008 till December 2010 to collect as many respondents as
possible. The reason for amniocentesis or CVS was advanced
maternal age and/or an increased risk at first trimester com-
bined test (nuchal translucency (NT) < 3.5mm). The com-
bined test comprised three markers, that is, maternal serum
beta human chorionic gonadotropin (beta-hCG), maternal
serum pregnancy-associated plasma protein-A (PAPP-A),
and ultrasound measurement of NT. These three markers
together with maternal age provided a patient-specific risk.
Women with a fetal NT > 3.5mm were not included. A fetal
NT > 3.5mm can be associated with structural malforma-
tions, other genetic syndromes, or submicroscopic aberra-
tions and examined best by genome-wide testing (e.g., by
microarray analysis).
Women were from hospitals participating in the Network
Prenatal Diagnostics Nijmegen (NPDN) consisting of the
Radboud University Medical Centre (hospital A) and four
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Table 2: Data about the general attitude of women about having the option to choose between prenatal tests.
Strongly
agree
N (%)
Somewhat
agree
N (%)
Neither agree
nor disagree
N (%)
Somewhat
disagree
N (%)
Strongly
disagree
N (%)
Total
N (%)
Do you agree that pregnant women should have the option to
choose between tests.
628
(76.5)
176
(21.4)
7
(0.9)
6
(0.7)
4
(0.5)
821
(100)
Pregnant women are capable to choose between tests. 423(51.6)
316
(38.5)
28
(3.4)
40
(4.9)
13
(1.6)
820
(100)
The choice can be best made by a professional. 45
(5.5)
226
(27.6)
105
(12.8)
335
(40.9)
109
(13.3)
820
(100)
Choosing between tests places a burden to pregnant women. 32(4.1)
112
(14.1)
81
(10.3)
366
(46.3)
199
(25.2)
790
(100)
satellite clinics, that is, Rijnstate Hospital Arnhem (hospital
B), St. Elisabeth Hospital and TweeSteden Hospital Tilburg
(hospital C), Medical Spectrum Twente Enschede (hospital
D), and Jeroen Bosch Hospital’s Hertogenbosch (hospital E),
all following the same standards of prenatal diagnostic care
and covering the southeast part of The Netherlands.
Aftermaking an appointment for invasive testing, written
information was sent to the women. In all hospitals, women
were offered a prenatal counseling although counseling var-
ied in time and type of professional. In hospitals A and E, the
genetic counseling session generally lasted about 30 minutes
and was performed by a genetic counselor or medical doctor,
respectively. In hospitals B (medical doctor), C (genetic
counselor), and D (medical doctor), this procedure lasted
about 5 minutes.
In 1332 of the cases (97.3%), the women received a normal
test result on their amniocentesis or CVS, and in 38 of the
cases (2.7%) the women received an abnormal test result
(trisomy 21 𝑁 = 31; trisomy 18 𝑁 = 1; sex chromosomal
aberration 𝑁 = 6). These latter women were asked if they
would be willing to participate in the study before the
questionnaire was sent out (nonanonymous).
A 10-question self-designed questionnaire was used to
collect data on satisfaction with having the option to choose
between the two types of diagnostic tests. The questions were
categorized into three groups: (a) personal characteristics
(age, education level, test of choice, and prenatal centre), (b)
general attitudes towards having a choice, and (c) questions
about the personal experience with having a choice. Category
(b) comprised four questions, each with a 5-point rating scale
ranging from strongly disagree to strongly agree. Category
(c) comprised closed-ended questions with the possibility to
answer yes or no, however, with the option to add a personal
comment. Questionnaires had to be returned within six
months.The data was analyzed using a Statistical Package for
the Social Sciences (SPSS) software package. Chi-square tests
were used to determine if there were statistically significant
differences between responses (𝑃 < 0.05).
3. Results
Eight hundred and twenty-five (825) completed surveys were
returned. Thirty-five of the 1370 surveys were sent out to
a wrong address, leaving a total evaluable sample of 1335,
resulting in a response rate of 61.8%.
Therewere 38womenwhohad received an abnormal fetal
test result. Only 12 out of these 38 (31.6%) responded (trisomy
21𝑁 = 8; trisomy 18𝑁 = 1; 47, XXY𝑁 = 2; mosaic 45, X/46,
XY 𝑁 = 1), which is much lower than the overall response.
Not all responding women answered all survey items, which
resulted in a variable number of respondents per question.
The mean maternal age of the respondents was 38.0 ± 2.8
years (mean ± standard deviation). Just over half (55.0%)
followed a higher professional education or university. In
52.7%, the test of preference was karyotyping, 40.5% of the
respondents chose to have a rapid targeted test, and 5.6%
did not remember the type of test they underwent. The
respondentswerewomen recruited from5different locations:
hospital A (35.4%), hospital B (22.7%), hospital C (11.4%),
hospital D (11.6%), and hospital E (18.9%). An overview of
all personal characteristics is shown in Table 1.
3.1. Respondent’s General Attitude about Having the Option
to Choose. Almost all respondents (97.9%) agreed that preg-
nant women should have the possibility to choose between
tests, and 90.1% indicated that pregnant women are able to
choose between both tests. Nevertheless, one-third of the
respondents (33.1%) suggested that the choice can best be
made by a professional. In 18.2%, choosing between tests was
experienced as a burden to pregnant women. An overview
of all respondents’ general attitude about having a choice in
prenatal testing is shown in Table 2.
3.2. Respondent’s Personal Experience aboutHaving theOption
to Choose. Regret was indicated by ten (1.2%) women: in
six a rapid targeted test was the test of choice, three chose
karyotyping, and one did not remember which test was done.
Comments from these respondents are shown in Table 3.
In two cases, the test of choice could not be performed
because of technical reasons (case id 59 and 463). In two
cases (case id 266 and 725), detection of a fetal heart defect
during pregnancy followup at a later gestational age was
the reason for regret. They had chosen a rapid targeted
test, while the cardiac defect could be related to a (small)
cytogenetic aberration not detected with this test. The other
four respondents reported different personal reasons to have
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Table 3: Comments from the respondents who showed regret about their choice.
Case ID Test of choice Comment Type of comment Age Hospital
59 Karyotyping
“There was too little amniotic fluid to perform karyotyping and
therefore a rapid targeted test was the alternative test. I preferred
karyotyping.”
Technical aspect 39 E
171 Karyotyping “The option to choose was offered just before the procedure. Ihad my doubts and subsequently, I regret my decision.” Personal aspect 39 B
266 Rapid targeted test “Later in pregnancy a fetal heart defect was detected, possiblycaused by a chromosomal aberration” Medical aspect 40 B
463 Rapid targeted test
“Our test of choice was a rapid targeted test, contamination with
blood made the test result unreliable. Unfortunately, we had to
wait 3 weeks to obtain the karyotyping result”
Technical aspect 39 B
673 Karyotyping “I will never make that choice again” Personal aspect 33 A
725 Rapid targeted test
“Later in pregnancy a fetal heart defect was detected. We were
uncertain whether this was caused by a chromosomal
aberration”
Medical aspect 38 E
729 Unknown “It went against all my feelings” Personal aspect 40 A
745 Rapid targeted test “In my previous pregnancy karyotyping was performed. It feelsbetter when they examine more” Personal aspect 38 E
Table 4: Data of personal experiences about the option to choose.
Number %
Do you regret the choice you made?
(𝑁 = 823)
No 811 98.5
Yes 8 1.0
Not applicable 1 0.1
Regret of invasive procedure 3 0.4
Did you make the decision freely? (𝑁 = 819)
No 29 3.5
Yes 788 96.2
Not applicable 2 0.3
Did the opinion of others influence your
choice? (𝑁 = 824)
No 289 35.1
Yes, the professional 86 10.4
Yes, my partner 237 28.8
Yes, both professional and partner 163 19.8
Yes, both professional, partner, and others 49 5.9
Do you want to have the possibility to choose
again in a next pregnancy? (𝑁 = 821)
No, I prefer to have the choice made by the
professional 22 2.7
Yes 795 96.8
Not applicable 4 0.5
regrets: the time to decide was too short; doubt, inability to
make a choice, and familiarity with karyotyping in a previous
pregnancy were the aspects they mentioned.
Three other pregnancies ended in fetal demise. These
respondents also showed regret but not because of the
choice they made but because they underwent the invasive
procedure. Two of themdid not have an invasive procedure in
a following pregnancy.Three of the four womenwho received
an abnormal diagnostic test result and chose to have a rapid
targeted test reported that theywere positive about having the
test result so quickly.
Although decision making was influenced by others in
64.9% of thewomen (influence of partner 28.8%, professional
10.4%, and combination of partner, professional, and others
25.7%), most of the women (96.2%) felt they made the choice
freely and were able to follow their personal perspectives.
In a next pregnancy, 2.7% of the respondents preferred
to have the choice to be made by the professional; however,
the majority (96.8%) wanted to have the possibility to choose
again. An overview of all respondents’ personal experiences
about having a choice in prenatal testing is shown in Table 4.
On the basis of the maternal age distribution, the mean
maternal age of women preferring a rapid targeted test or
karyotyping was 37.7 years ± 3.03 SD and 38.3 years ± 2.60
SD, respectively. Karyotyping appeared the preferred test in
the group with advanced maternal age (48.5%) compared to
women younger than 36 years (34.5%).
Regarding the respondents’ test of preference, we
observed considerable and statistically significant differences
between hospitals A and E (Table 5). In hospital A, 31.2%
preferred a rapid targeted test, and 63.0% chose to have
karyotyping, while in hospital E the opposite was the case:
60.1% and 32.7%, respectively (𝑃 < 0.001, chi-square test).
Examination of both populations showed no differences in
the level of education or in having regret of their choice.
Differences were seen in age distribution and influence
of others: the population in hospital E comprised more
respondents <36 years (𝑃 = 0.004). Although both hospitals
A and E apply a 30-minute counseling regime, the influence
of others on choicemaking was higher in hospital E
(𝑃 = 0.025). Nevertheless, women from both hospitals
appeared positive about their choice.
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Table 5: Characteristics of the respondents of the two hospitals A and E.
Hospital A (%) Hospital E (%) P-value
Test of choice <0.001
Rapid targeted test 31.2 59.5
Karyotyping 63.0 33.3
Education level
Lower vocational, lower secondary school 1.1 0.6
Intermediate and higher vocational, higher secondary school 41.4 42.6
College/university 57.5 56.8
Maternal age 0.004
<35 6.3 15.0
≥36 93.7 85.0
Regret
No 99.3 98.1
Influence 0.025
No 36.0 25.2
Yes: 64.0 74.8
(i) Professional 5.5 13.5
(ii) Partner 39.3 21.9
(iii) Professional and partner 12.0 32.9
(iv) Professional, partner, and others 7.2 6.5
4. Discussion
Our results show that more than 90% of the pregnant women
who answered the questionnaire expressed a positive attitude
towards the option to choose between karyotyping and rapid
targeted testing. Although most of the women (64.9%) felt
influenced by their physicians and their partners, themajority
(96.2%) had the impression that they were free to choose
and to follow their individual perspectives. The question of
whether the option to choose places a burden to women was
answered positively in 18.4% of the respondents; however,
almost all women in our cohort (96.4%) preferred to have the
option to choose again in a next pregnancy.
Ethical discussions about the desirability of offering
different prenatal tests focus mainly on the autonomy of the
women involved. A growing consensus is that women will
only benefit from the test offer when they are able to make
an autonomous decision [12]. Our study shows that most
women, although influenced by others, are positive about
choice making. In 50% and 46.1%, respectively, respondents
with a lower educational or middle education level preferred
the choice to be best made by a professional, while this was
29.9% in the group of respondents with a high educational
level. This is in line with Verlinde et al., 2012, concluding
that a lower preference for a shared decision making style
is noticed in lower education people [13]. Patients with a
higher educational level also tend to participate more in
the consultation in terms of asking questions and asking
for explanations and clarification than patients from a lower
educational level.
Regarding the respondents’ test of preference, a consider-
able and statistically significant difference between hospitals
A and E (Table 5) was observed. Next to the small differences
in age distribution and influence of others, also provider
beliefs and bias in counseling might have played a role.
In this era of rapid developments in genetic testing and
growing societal individualization, a uniform test policy
seems rather out of date while, not only in healthcare,
autonomy is increasing. From an ethical point of view, the
best approach appears to be to offering women a choice
between rapid targeted testing and karyotyping [14]. In a
previous Dutch study of Boormans et al. on the impact of
karyotyping and rapid targeted testing on quality of life,
women showed a clear preference for rapid targeted testing
or karyotyping. Despite individual differences, their study
showed no systematic differences in time of stand-alone
rapid targeted testing versus karyotyping in terms of anxiety,
general physical and mental health, and stress [15].
A limitation of our study is that participants provided the
data after they had received their diagnostic test result. Thus,
it is possible that attitudes were influenced by the stage of
decision making and may have served, to some extent, as a
post hoc justification for the choice. A second limitation is
that the timespan between sampling and having the question-
naire varied between 4 and 28 months. It might be possible
that respondents’ attitudes and experiences have changed in
time.This large timespan could also have influenced women’s
participation andmight be an explanation of the low response
rate (61.8%).
Although the group of respondents who received an
abnormal test result was small (1.5%), women indicated to
feel positive about having a test result quickly after they
chose to have a rapid targeted test. Clearly, prospective
studies are needed to examine this possible effectmore clearly
and examine choice of testing and likelihood of pregnancy
termination.
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In comparison with rapid targeted testing, a slightly
higher preference for karyotyping (52.7%) was indicated. A
reason for this preference might be that karyotyping will
detect all microscopically visible chromosomal abnormalities
or respondents are already familiar with karyotyping. How-
ever, this result is not representative for the test preference
in our daily practice. During the last year, the preference for
rapid targeted testing was 60% versus 40% for karyotyping.
Rapid targeted tests have shown to improve cost-effect-
iveness as compared to karyotyping [16–18]. This appeared
most beneficial when rapid targeted tests were applied as a
replacement for karyotypingwithin larger laboratories (>1100
specimens per annum).However, including an individualized
choice, assuming that 50% choose karyotyping and 50% a
rapid targeted test, already has a major impact on costs [17].
While individual choice as a strategy is less efficient than a
uniform strategy in which every patient would receive a rapid
targeted test, an overall cost reduction remains in comparison
with karyotyping [17].
We conclude that respondents expressed a positive atti-
tude towards the option to choose.The application of offering
a choice in prenatal tests will, however, depend on preference
of the prenatal centre and is mainly driven by sample
throughput, overall costs, and the national health system
concerned.
4.1. What’s Already Known about This Topic?
(i) Offering an individualized choice in prenatal diagno-
sis is an appropriate strategy.
4.2. What Does This Study Add?
(i) The study gives us more insight in testing behavior
and women’s perceptions associated with having a
choice between rapid targeted testing and karyotyp-
ing.
(a) We revealed attitudes and experiences of
women towards invasive prenatal diagnosis in
case they were offered a real choice between a
rapid targeted test and regular karyotyping.
(b) Women expressed a positive attitude towards
the option to choose.
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